The effect of thromboxane A2 (TXA2) synthase inhibitor (Ozagrel) on difficult to treat chough variant asthma (CVA).
Not Applicable
- Conditions
- cough variant asthma
- Registration Number
- JPRN-UMIN000015512
- Lead Sponsor
- Graduate School of Medical Sciences, Nagoya City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with suspicion of infectious disease such as pulmonary tuberculosis. 2. Current smoker, ex-smoker with smoking history within 6 months, ex-smoker with smoking history more than 5 pack-years. 3. Gastroesophageal reflux disease patients with scores of Frequency Scale for the Symptoms of GERD (FSSG) more than eight. 4. Patients with tendency to hemorrhages. 5. Patients who takes histamine H1 receptor antagonist, anti-thromboxane agent, angiotensin converting enzyme inhibitor, or Non-Steroidal Anti-Inhlammatory Drugs.
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response of cough symptoms
- Secondary Outcome Measures
Name Time Method 1) Improvement of capsaicin cough sensitivity. 2) Changes of Thromboxane B2 (TXB2)concentration in sputum. Correlation between changes of TXB2 concentration and a) Changes of scores in Leister cough questionnaire b) Improvement of capsaicin cough sensitivity c) Falling rate of sputum eosinophil count d) Reduction rate of fractional exhaled nitric oxide and improvement of spirometry , Impulse Oscillation System. e) Changes of MUC5AC concentration.